encouraging slightly better overall diagnostic performance and practical/ technical advantages in favor of 18F-fluciclovine as compared with the routine tracer. Enrolment and further analyses (region-based/semiquantitative/uni-multivariate-logistic-regression to evaluate predictive factors) are ongoing.
INTRODUCTION AND OBJECTIVES: With current standard cross-sectional imaging (CT or MRI) detection of prostate cancer lesions in patients with biochemical recurrence (BCR) after radical prostatectomy remains challenging, especially at low PSA values. Recently, 68Ga-PSMA PET imaging has been shown to improve detection rates. However, up to now published case series include only a limited number of patients at low PSA values.
METHODS: For this retrospective analysis 272 pts with BCR after radical prostatectomy were extracted from the institutional database who presented with a PSA value from 0.2 up to 1ng/ml at the time of 68Ga-PSMA PET/CT imaging. 68Ga-PSMA PET/CT was evaluated by one experienced reader for lesions suggestive for prostate cancer recurrence and site of suspicious lesions was reported. Patients were grouped according to PSA value, from 0.2 e 0.5ng/mL and from >0.5 e 1.0ng/mL. Primary T-, N-stage, Gleason-Score, D'Amico-Classification, previous local radiation therapy as well as concurrent androgen deprivation therapy (ADT) was correlated to detection rates.
RESULTS: In total, in 54.5 % (73/134) of patients with PSA from 0.2 e 0.5ng/mL and in 76.1% (102/134) of patients with PSA >0.5 e 1.0ng/mL suspicious findings on 68Ga-PSMA PET/CT imaging were noted. Sites of recurrence were local (37.0% and 41.2%), pelvic or retroperitoneal lymph nodes (45.2% and 54.9%), bone (24.7% and 29.4%), supradiaphragmal lymph nodes (6.8% and 6.9%) as well as others (4.1% and 2.0%). In patients with primary locally advanced tumors (pT>3a), primary N+ disease, Gleason-Scores >8, primary higher D'Amico-Classification, previous radiation therapy as well as with concurrent ADT positive findings on 68Ga-PSMA PET/ CT were more likely compared to patients without these characteristics.
CONCLUSIONS: 68Ga-PSMA PET/CT is able to identify sites of recurrent prostate cancer after radical prostatectomy even at low PSA values up to 1ng/ml in a significant number of patients e especially in patients with primary more aggressive tumor characteristics, previous local radiation therapy or concurrent ADT e and thus will very likely present the future imaging technique in these patients. As salvage therapies (local radiation therapy, salvage lymph node dissection or PSMA-radioguided surgery) are most effective at low PSA-levels, early detection of cancerous foci by 68Ga-PSMA PET might even improve oncological results. INTRODUCTION AND OBJECTIVES: The aim of this retrospective study was to evaluate the detection rate of 68Ga-PSMA PET/ CT in a homogeneous patient population with biochemical recurrent prostate cancer defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment and who had not undergone previous salvage prostatectomy.
METHODS: After screening of our institutional database 118 patients were finally eligible for this retrospective analysis with a median PSA of 6.4 ng/mL (range: 2.2 -158.4 ng/mL). 77 and 41 patients had been treated by EBRT or brachytherapy, respectively. Of the 118 patients, 45 were receiving androgen deprivation therapy (ADT) within at least 6 months prior to 68Ga-PSMA PET/CT. The detection rates were stratified by PSA (2 to <5, 5 to <10 and ¼10 ng/mL). The influence of primary Gleason score at diagnosis and ADT was assessed. Correlations between standardized uptake values (SUV) and Gleason score or ADT in patients with positive findings were analyzed. RESULTS: 90.7% (107/118) patients showed pathological findings indicative for tumor recurrence in 68Ga-PSMA PET/CT. The detection rates were 81.8% (36/44), 95.3% (41/43) and 96.8% (30/31) for PSA ranges of 2 to <5, 5 to <10 and ¼10 ng/mL, respectively. 68Ga-PSMA PET/CT indicated local recurrence in 68/107 patients (63.5%), only distant lesions in 64/105 patients (59.8%) and local recurrence as well as distant lesions in 25/107 patients (23.4%). The detection rate was significantly higher in patients with ADT (97.7%) vs. without ADT (86.3%, p¼0.0381), but independent from primary Gleason score ¼8 (92.0%) vs. ¼7 (90.2%, p¼0.6346). SUVmax and SUVmean were significantly higher in patients with ADT (p¼0.0025 and 0.0044, respectively) and a clear trend to higher values was observed for patients with Gleason score ¼8 (p¼0.0502 and 0.0514, respectively).
CONCLUSIONS: 68Ga-PSMA PET/CT demonstrates high detection rates in patients with biochemical recurrence of prostate cancer after primary radiation therapy as defined by Phoenix criteria. The detection rate positively correlated to increasing PSA as well as concomitant ADT. 68Ga-PSMA PET/CT enables discrimination of local vs. systemic disease and thus might have a crucial impact on further clinical management. The high observed detection rates even at very low PSA values questions the definition of recurrence by the current Phoenix criteria. A limitation of this study is the lack of histopathological proof in the majority of patients. INTRODUCTION AND OBJECTIVES: US-MRI fusion biopsy (FB) showed that it improves the detection of clinically significant prostate cancer (PCa). A more accurate diagnostic method is desirable to avoid misclassification, which in turn is particularly important in appropriate decision making on treatment for PCa (active surveillance or focal therapy or radical treatment). We aimed to compare the Gleason upgrading (GU) rates and the concordance of the Gleason scores in the biopsy versus final pathology after the surgery in patients who e1188
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